|
Abstract Objective: To explore the clinical effect of Gangliosides Sodium combined with Meropenem in the treatment of neonatal purulent meningitis (PM). Method: A total of 72 children with PM admitted to Xinyu Maternal and Child Health Hospital from January 2018 to October 2019 were selected, they were divided into two groups according to different treatment methods, with 36 cases in each group. The control group was treated with Meropenem, and the observation group was treated with Gangliosides Sodium on the basis of the control group. The clinical efficacy, improvement time of symptoms, serological indexes [C reactive protein (CRP), procalcitonin (PCT), neuron-specific enolase (NSE) and calcitonin gene-related peptide (CGRP)], cerebrospinal fluid indexes and adverse reactions were compared between the two groups. Result: The total effective rate in the observation group was 94.44% (34/36), which was higher than 77.78% (28/36) in the control group, the difference was statistically significant (P<0.05). The improvement time of fever, vomiting and intracranial hypertension in the observation group was (1.89±0.24), (2.36±0.28) and (2.75±0.34) d, respectively, which were shorter than (2.78±0.27), (3.41±0.35) and (3.87±0.41) d in the control group, the differences were statistically significant (P<0.05). The serum CRP, PCT, NSE and CGRP in the observation group were (6.12±1.25) mg/L, (0.58±0.11) μg/L, (10.25±1.43) μg/L, (20.36±2.18) μg/L, respectively, which were lower than (8.34±1.31) mg/L, (0.89±0.13) μg/L, (13.57±1.48) μg/L, (24.65±2.27) μg/L in cerebrospinal fluid in the control group, the differences were statistically significant (P<0.05). The CRP, PCT, NSE and CGRP in the observation group were (4.12±0.49) mg/L, (0.41±0.08) μg/L, (13.25±2.01) μg/L, (15.63±2.02) μg/L, respectively, they were lower than (5.28±1.06) mg/L, (0.62±0.12) μg/L, (16.24±2.08) μg/L,
|
|
Received: 23 September 2022
|
|
|
|
